Phase II study of necitumumab plus modified FOLFOX6 as first-line treatment in patients with locally advanced or metastatic colorectal cancer

被引：0
|
作者：
E Elez
A Hendlisz
T Delaunoit
J Sastre
A Cervantes
R Varea
G Chao
J Wallin
J Tabernero
机构：
[1] Vall d’Hebron Institute of Oncology Barcelona,
[2] Spain and Universitat Autònoma de Barcelona,undefined
[3] Institut Jules Bordet,undefined
[4] Centres Hospitaliers Jolimont,undefined
[5] Hospital Universitario San Carlos,undefined
[6] Biomedical Research Institute INCLIVA,undefined
[7] University of Valencia,undefined
[8] Eli Lilly and Company,undefined
[9] Eli Lilly and Company,undefined
[10] Eli Lilly and Company,undefined
来源：
British Journal of Cancer | 2016年 / 114卷
关键词：
advanced colorectal cancer; modified FOLFOX6; necitumumab; KRAS; EGFR;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：372 / 380
页数：8
相关论文
共 50 条
  • [31] Biweekly Cetuximab Plus FOLFOX6 as First-Line Therapy in Patients With RAS Wild-Type Metastatic Colorectal Cancer: The CEBIFOX Trial
    Kasper, Stefan
    Meiler, Johannes
    Knipp, Heike
    Hohler, Thomas
    Reimer, Peter
    Steinmetz, Tilman
    Berger, Winfried
    Linden, Gabriele
    Reis, Henning
    Markus, Peter
    Paul, Andreas
    Dechene, Alexander
    Schumacher, Brigitte
    Kostbade, Karina
    Virchow, Isabel
    Ting, Saskia
    Worm, Karl
    Schmid, Kurt W.
    Herold, Thomas
    Wiesweg, Marcel
    Schuler, Martin
    Trarbach, Tanja
    CLINICAL COLORECTAL CANCER, 2020, 19 (04) : 236 - +
  • [32] A phase II study of neoadjuvant chemotherapy with a modified FOLFOX6 regimen for locally advanced gastric cancer.
    Wang, Xiang
    Zhao, Lin
    Liu, Hongfeng
    Bai, Chunmei
    Li, Xiaoyi
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [33] Phase 3 study of tucatinib, trastuzumab, and modified FOLFOX6 as first-line treatment in HER2+metastatic colorectal cancer (MOUNTAINEER-03, trial in progress)
    Fritsch, R.
    Andre, T.
    Bekaii-Saab, T.
    Cercek, A.
    Nakamura, Y.
    Raghav, K.
    Siena, S.
    Strickler, J.
    Van Cutsem, E.
    Adelberg, D.
    Ramos, J.
    Yang, S.
    Yoshino, T.
    Tabernero, J.
    SWISS MEDICAL WEEKLY, 2023, 153 : 70S - 70S
  • [34] Phase 3 study of tucatinib, trastuzumab, and modified FOLFOX6 as first-line treatment in HER2+metastatic colorectal cancer (MOUNTAINEER-03, trial in progress)
    Heinemann, Volker
    Andre, Thierry
    Bekaii-Saab, Tanios
    Cercek, Andrea
    Nakamura, Yoshiaki
    Raghav, Kanwal
    Siena, Salvatore
    Strickler, John
    Van Cutsem, Eric
    Adelberg, David
    Ramos, Jorge
    Yang, Shan
    Yoshino, Takayuki
    Tabernero, Josep
    ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 60 - 60
  • [35] Phase 3 study of tucatinib, trastuzumab, and modified FOLFOX6 as first-line treatment in HER2+metastatic colorectal cancer (MOUNTAINEER-03, trial in progress)
    Heinemann, V.
    Bekaii-Saab, T.
    Van Cutsem, E.
    Tabernero, J.
    Siena, S.
    Yoshino, T.
    Nakamura, Y.
    Raghav, K.
    Cercek, A.
    Adelberg, D.
    Ramos, J.
    Yang, S.
    Andre, T.
    Strickler, J.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 159 - 160
  • [36] Survival analysis of colorectal cancer patients treated with first-line modified FOLFOX6 with or without bolus fluorouracil.
    Shaib, Walid Labib
    Draper, Amber
    Kalu, Kalu
    Byers, Kristina F.
    El-Rayes, Bassel F.
    Wu, Christina
    Alese, Olatunji B.
    Akce, Mehmet
    Goyal, Subir
    Zakka, Katerina Mary
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [37] The ATOM trial: A multicenter, randomized phase II study of modified FOLFOX6 plus bevacizumab and modified FOLFOX6 plus cetuximab for colorectal cancer with liver-limited metastases.
    Emi, Yasunori
    Muro, Kei
    Yamanaka, Takeharu
    Katayose, Yu
    Uetake, Hiroyuki
    Sugihara, Kenichi
    Kakeji, Yoshihiro
    Unno, Michiaki
    Hyodo, Ichinosuke
    Tomita, Naohiro
    Maehara, Yoshihiko
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [38] Phase I trial of erlotinib (E), modified FOLFOX6 (mFOLFOX6), and bevacizumab (B) as first-line therapy for metastatic colorectal cancer (MCRC)
    Singh, D.
    Rath, L.
    Bokar, J. A.
    Brell, J. M.
    Cooney, M. M.
    Dowlati, A.
    Gibbons, J.
    Nock, C. J.
    Savvides, P.
    Krishnamurthi, S. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [39] FOLFOX plus cetuximab in first-line therapy of advanced colorectal cancer
    Ehrenberg, Roland
    Halama, Niels
    ANNALS OF TRANSLATIONAL MEDICINE, 2018, 6
  • [40] Phase II study of capecitabine plus oxaliplatin for the first-line treatment of patients with metastatic colorectal carcinoma
    Xu, R.
    Li, Y.
    Luo, H.
    Wang, F.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
12345